Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) – Equities researchers at Dawson James lifted their FY2022 EPS estimates for Lineage Cell Therapeutics in a note issued to investors on Monday, November 21st. Dawson James analyst J. Kolbert now expects that the company will post earnings per share of ($0.15) for the year, up from their previous forecast of ($0.17). The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.16) per share. Dawson James also issued estimates for Lineage Cell Therapeutics’ Q4 2022 earnings at ($0.03) EPS, FY2023 earnings at ($0.20) EPS, FY2024 earnings at ($0.24) EPS, FY2025 earnings at ($0.22) EPS and FY2026 earnings at $1.44 EPS.
Separately, Robert W. Baird assumed coverage on shares of Lineage Cell Therapeutics in a report on Tuesday, November 1st. They issued an “outperform” rating and a $5.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $5.40.
Lineage Cell Therapeutics Price Performance
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its holdings in Lineage Cell Therapeutics by 18.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 72,400 shares of the company’s stock valued at $114,000 after buying an additional 11,309 shares during the period. Wealth Architects LLC acquired a new stake in shares of Lineage Cell Therapeutics during the first quarter worth approximately $25,000. Charles Schwab Investment Management Inc. boosted its holdings in Lineage Cell Therapeutics by 5.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 332,406 shares of the company’s stock worth $512,000 after purchasing an additional 17,052 shares during the period. Mirabella Financial Services LLP acquired a new position in Lineage Cell Therapeutics in the first quarter worth $29,000. Finally, Fort Sheridan Advisors LLC lifted its stake in Lineage Cell Therapeutics by 43.5% in the first quarter. Fort Sheridan Advisors LLC now owns 75,931 shares of the company’s stock valued at $117,000 after buying an additional 23,000 shares during the last quarter. 38.29% of the stock is currently owned by hedge funds and other institutional investors.
About Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Lineage Cell Therapeutics (LCTX)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.